Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020;395:200–11. https://doi.org/10.1016/S0140-6736(19)32989-7.

Article  Google Scholar 

Paoli CJ, Reynolds MA, Sinha M, Gitlin M, Crouser E. Epidemiology and costs of sepsis in the united states—an analysis based on timing of diagnosis and severity level*. Crit Care Med. 2018;46:1889–97. https://doi.org/10.1097/CCM.0000000000003342.

Article  PubMed  PubMed Central  Google Scholar 

Vincent J-L, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. 2019;23:196. https://doi.org/10.1186/s13054-019-2478-6.

Article  PubMed  PubMed Central  Google Scholar 

Mostel Z, Perl A, Marck M, Mehdi SF, Lowell B, Bathija S, et al. Post-sepsis syndrome—an evolving entity that afflicts survivors of sepsis. Mol Med. 2020;26:6. https://doi.org/10.1186/s10020-019-0132-z.

Article  CAS  Google Scholar 

Fleischmann C, Hartmann M, Hartog C, Welte T, Heublein S, Thomas-Rueddel D, et al. Epidemiology of sepsis in Germany: incidence, mortality and associated costs of care 2007–2013. Intensive Care Med Exp. 2015;3:A50. https://doi.org/10.1186/2197-425X-3-S1-A50.

Article  PubMed Central  Google Scholar 

Lescroart M, Pequignot B, Kimmoun A, Klein T, Levy B. Beta-blockers in septic shock: What is new? J Intensive Med. 2022;2:150–5. https://doi.org/10.1016/j.jointm.2022.01.004.

Article  PubMed  PubMed Central  Google Scholar 

Scholz SS, Borgstedt R, Ebeling N, Menzel LC, Jansen G, Rehberg S. Mortality in septic patients treated with vitamin C: a systematic meta-analysis. Crit Care. 2021;25:17. https://doi.org/10.1186/s13054-020-03438-9.

Article  PubMed  PubMed Central  Google Scholar 

Bruning R, Dykes H, Jones TW, Wayne NB, Sikora Newsome A. Beta-adrenergic blockade in critical illness. Front Pharmacol. 2021. https://doi.org/10.3389/fphar.2021.735841.

Article  PubMed  PubMed Central  Google Scholar 

Belletti A, Landoni G, Lomivorotov VV, Oriani A, Ajello S. Adrenergic downregulation in critical care: molecular mechanisms and therapeutic evidence. J Cardiothorac Vasc Anesth. 2020;34:1023–41. https://doi.org/10.1053/j.jvca.2019.10.017.

Article  CAS  PubMed  Google Scholar 

Rehberg S, Joannidis M, Whitehouse T, Morelli A. Landiolol for managing atrial fibrillation in intensive care. Eur Heart J Suppl. 2018;20:A15–8. https://doi.org/10.1093/eurheartj/sux039.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock. JAMA. 2013;310:1683. https://doi.org/10.1001/jama.2013.278477.

Article  CAS  PubMed  Google Scholar 

Wang Z, Wu Q, Nie X, Guo J, Yang C. Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective. Randomized Trial Clin Drug Investig. 2015;35:707–16. https://doi.org/10.1007/s40261-015-0325-3.

Article  CAS  PubMed  Google Scholar 

Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, et al. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2020;8:863–72. https://doi.org/10.1016/S2213-2600(20)30037-0.

Article  CAS  PubMed  Google Scholar 

Whitehouse T, Hossain A, Perkins GD, Gordon AC, Bion J, Young D, et al. Landiolol and organ failure in patients with septic shock. JAMA. 2023;330:1641. https://doi.org/10.1001/jama.2023.20134.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rehberg S, Frank S, Černý V, Cihlář R, Borgstedt R, Biancofiore G, et al. Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med. 2024;50(10):1622–34. https://doi.org/10.1007/s00134-024-07587-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Gao X, He Z, Wang J, Xu G, Li T. Evaluating the effects of Esmolol on cardiac function in patients with Septic cardiomyopathy by Speck-tracking echocardiography—a randomized controlled trial. BMC Anesthesiol. 2023;23:51. https://doi.org/10.1186/s12871-023-01983-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cocchi MN, Dargin J, Chase M, Patel PV, Grossestreuer A, Balaji L, et al. Esmolol to treat the hemodynamic effects of septic shock: a randomized controlled trial. Shock. 2022;57:508–17. https://doi.org/10.1097/SHK.0000000000001905.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang S, Liu Z, Yang W, Zhang G, Hou B, Liu J, et al. Effects of the β-blockers on cardiac protection and hemodynamics in patients with septic shock: a prospective study. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26:714–7. https://doi.org/10.3760/cma.j.issn.2095-4352.2014.10.007.

Article  PubMed  Google Scholar 

Xinqiang L, Weiping H, Miaoyun W, Wenxin Z, Wenqiang J, Shenglong C, et al. Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27:759–63.

PubMed  Google Scholar 

Wang S, Li M, Duan J, Yi L, Huang X, Chen D, et al. Effect of esmolol on hemodynamics and clinical outcomes in patients with septic shock. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017;29:390–5. https://doi.org/10.3760/cma.j.issn.2095-4352.2017.05.002.

Article  PubMed  Google Scholar 

Liu H, Ding XF, Zhang SG, Wang HX, Luo YG, Duan XG, Liu SH, Zhang RF, Zhang XJ, Qin CH, Han B, Wang Y, Sun TW. Effect of esmolol in septic shock patients with tachycardia: a randomized clinical trial. Zhonghua Yi Xue Za Zhi. 2019;99(17):1317–22. https://doi.org/10.3760/cma.j.issn.0376-2491.2019.17.009. (Chinese).

Article  CAS  PubMed  Google Scholar 

Du W, Wang X-T, Long Y, Liu D-W. Efficacy and safety of esmolol in treatment of patients with septic shock. Chin Med J (Engl). 2016;129:1658–65. https://doi.org/10.4103/0366-6999.185856.

Article  CAS  PubMed  Google Scholar 

Chacko C, Gopal S. Systematic review of use of β-blockers in sepsis. J Anaesthesiol Clin Pharmacol. 2015;31:460. https://doi.org/10.4103/0970-9185.169063.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanfilippo F, Santonocito C, Morelli A, Foex P. Beta-blocker use in severe sepsis and septic shock: a systematic review. Curr Med Res Opin. 2015;31:1817–25. https://doi.org/10.1185/03007995.2015.1062357.

Article  CAS  PubMed  Google Scholar 

Heliste M, Pettilä V, Berger D, Jakob SM, Wilkman E. Beta-blocker treatment in the critically ill: a systematic review and meta-analysis. Ann Med. 2022;54:1994–2010. https://doi.org/10.1080/07853890.2022.2098376.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Takahashi K, Yatabe T, et al. Effect of ultrashort-acting β-blockers on mortality in patients with sepsis with persistent tachycardia despite initial resuscitation. Chest. 2021;159:2289–300. https://doi.org/10.1016/j.chest.2021.01.009.

Article  CAS  PubMed  Google Scholar 

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. https://doi.org/10.1186/2046-4053-4-1.

Article  PubMed  PubMed Central